Semaglutide

Generic Name
Semaglutide
Brand Names
Ozempic, Rybelsus, Wegovy
Drug Type
Small Molecule
Chemical Formula
C187H291N45O59
CAS Number
910463-68-2
Unique Ingredient Identifier
53AXN4NNHX
Background

Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. Other members of this drug class include Exenatide and Liraglutide. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. Th...

Indication

Semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus, and is used as an adjunct to diet and exercise. However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not in...

Associated Conditions
BMI >27 kg/m2, Cardiovascular Events, Obesity, Type 2 Diabetes Mellitus
Associated Therapies
Chronic Weight Management therapy
Clinical Trials
Related News

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

Phase 1
Not yet recruiting
Conditions
Polycystic Ovary Syndrome
Interventions
Drug: Semaglutide
First Posted Date
2024-01-24
Last Posted Date
2024-03-27
Lead Sponsor
Methodist Health System
Target Recruit Count
85
Registration Number
NCT06222437
Locations
🇺🇸

Clinical Research Institute at Methodist Health System, Dallas, Texas, United States

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Phase 3
Active, not recruiting
Conditions
Type 2 Diabetes
Interventions
Drug: Cagrilintide
Drug: Tirzepatide
Drug: Semaglutide
First Posted Date
2024-01-24
Last Posted Date
2024-11-20
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
1000
Registration Number
NCT06221969
Locations
🇺🇸

Univ of Alabama_Birmingham, Birmingham, Alabama, United States

🇺🇸

Prime Medical Group, LLC, Gilbert, Arizona, United States

🇺🇸

Velocity Clinical Research-Phoenix, Phoenix, Arizona, United States

and more 178 locations

A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight

Phase 1
Recruiting
Conditions
Obesity
Interventions
Drug: Cagrilintide
Drug: Placebo
Drug: Semaglutide
First Posted Date
2024-01-17
Last Posted Date
2024-03-15
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
180
Registration Number
NCT06207877
Locations
🇩🇪

Parexel International GmbH, Berlin, Germany

A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

Phase 3
Recruiting
Conditions
Type 2 Diabetes
Obesity
Interventions
Drug: IBI362
Drug: Semaglutide
First Posted Date
2023-12-28
Last Posted Date
2024-07-17
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
340
Registration Number
NCT06184568
Locations
🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

Phase 3
Active, not recruiting
Conditions
Obesity
Interventions
Drug: Cagrilintide
Drug: Tirzepatide
Drug: Semaglutide
First Posted Date
2023-11-14
Last Posted Date
2024-08-20
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
800
Registration Number
NCT06131437
Locations
🇺🇸

Univ of Alabama Birmingham, Birmingham, Alabama, United States

🇺🇸

Chambliss Clinical Trials LLC, Montgomery, Alabama, United States

🇺🇸

FDRC, Costa Mesa, California, United States

and more 42 locations

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

First Posted Date
2023-11-14
Last Posted Date
2024-11-21
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
618
Registration Number
NCT06131372
Locations
🇺🇸

Valley Research, Fresno, California, United States

🇺🇸

Desert Oasis Hlthcr Med Group, Palm Springs, California, United States

🇺🇸

John Muir Physicians Network, Concord, California, United States

and more 112 locations

Semaglutide Use in Acute Pulmonary Embolism

Completed
Conditions
Pulmonary Embolism
Interventions
Drug: Semaglutide
First Posted Date
2023-11-07
Last Posted Date
2023-11-07
Lead Sponsor
Imperial College London
Target Recruit Count
18
Registration Number
NCT06118203
Locations
🇬🇧

Colm McCabe, London, United Kingdom

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: Semaglutide
First Posted Date
2023-10-24
Last Posted Date
2024-07-19
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
121
Registration Number
NCT06097390
Locations
🇨🇦

Altasciences Clinical Company, Inc, Montreal, Quebec, Canada

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

First Posted Date
2023-10-16
Last Posted Date
2024-02-26
Lead Sponsor
Novo Nordisk A/S
Registration Number
NCT06083675
Locations
🇹🇭

Songklanagarind Hospital, Songkla, Thailand

🇬🇷

General Hospital of Thessaloniki "G.Papanikolaou", Thessaloniki, Greece

🇵🇱

ETG Siedlce, Siedlce, Masovian, Poland

and more 97 locations

Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes

First Posted Date
2023-10-13
Last Posted Date
2023-10-13
Lead Sponsor
Steno Diabetes Center Copenhagen
Target Recruit Count
2000
Registration Number
NCT06082063
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy